Status:
COMPLETED
Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Eligibility:
All Genders
18+ years
Brief Summary
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with ...
Eligibility Criteria
Inclusion
- Female or male patients, who are at \>=18 years
- Diagnosis of acute DVT and/or PE, objectively confirmed
- Indication for anticoagulation therapy for at least 12 weeks
- Willing to participate in this study and available for follow-up
Exclusion
- Exclusion criteria must be read in conjunction with the local product information.
Key Trial Info
Start Date :
June 27 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 20 2017
Estimated Enrollment :
1987 Patients enrolled
Trial Details
Trial ID
NCT02210819
Start Date
June 27 2014
End Date
January 20 2017
Last Update
August 29 2019
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Locations, Algeria
2
Multiple Locations, Egypt
3
Multiple Locations, Indonesia
4
Multiple Locations, Jordan